She discusses Structure, Enliven, Palvella, Moonlake, Evommune, and Oruka. Chapters General sentiment - 1:17 Structure Therapeutics - 4;29 Enliven - 7:50 Palvella - 10:43 Moonlake - 12:47 Evommune - 15:02 Oruka - 16:39

He shares his thoughts on recent data we have seen from mechanisms such as INHBE and amylin, why he's a big believer in oral therapies, and what other ares of biotech excite him today.

He describes his work in tropical disease, and how climate change has been elevating it in areas like the Gulf Coast of the United States. Plus, the importance of elevating scientists, what he has found works best for communicating with the public, and why he disagrees with the idea of 'hunkering down' until a day that science funding might rebound in the U.S.. Chapters Elevating scientists - 0:35 Tropical diseases - 7:20 Science communications - 15:30 Career advice for young

He shares his thoughts on the data, the competitive profile of this IL-2 Treg therapy vs JAK inhibitors, and how the overall platform looks for other I&I conditions.

Plus, discussions on key trial readouts outside of obesity: eplontersen, Lp(a), oral IL-23, and milvexian. Chapters Lilly - 0:48 Novo - 5:15 Zealand - 8:50 AstraZeneca / eplontersen - 10:44 Lp(a) / Novartis, Amgen, Lilly - 15:47 IL-23 / JNJ , Protagonist - 19:24 Milvexian / JNJ, Bristol 22:11 Note: A different division of HSBC, HSBC Innovation Banking, is a sponsor of BiotechTV

He discusses Praxis, Insmed, Ionis, PTC Therapeutics, Rapport, and United Therapeutics. Coverage brought to you by

He discusses Tyra, Sionna, Alumis, Nuvalent, and Monopar. Coverage brought to you by

His company is working on building a frontier model that has shown early success in outperforming bigger names in the field.

He discusses Insmed, IDEAYA, Bicycle, Compass Pathways, Revolution Medicines, Cytokinetics, and CG Oncology Chapters General sentiment - 1:25 Insmed - 3:16 IDEAYA - 7:07 Bicycle - 9:44 Compass Pathways - 13:04 Revolution, Cytokinetics, CG - 16:03

She highlights the goal of the accelerator, which meets monthly online, and also will have an in-person symposium in October. Plus, science that interests her, including "nodal" biologic pathways. Learn more about the Ladders to Cures Scientific Accelerator

She highlights a bill she has filed to help fill the gap left by reduced federal funding for research, and also the non-monetary initiatives, like quality of life, that the state can do to retain talent.

Michal Preminger will lead BioMed X Venture labs as CEO, and it will partner with pharma, foundations, and VCs to build mission driven companies.

MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Zag Bio CEO Jason Cole and Altido Therapeutics CEO Chip Clark about running early stage companies and what advice they have for new CEOs. They offer advice about what it will take to keep our ecosystem globally competitive. Chapters Zag Bio - 1:03 Altido Therapeutics - 2:12 Massachusetts - 3:00 Culture- 5:11 Different skill sets - 7:11 Getting through challenge - 9:12 Early stage companies - 15:27 F

He talks about Syncona's listed fund, and clarifies the details of a return of capital strategy for some shareholders, and he describes the strategy of the firm's new private fund. Plus, how Syncona thinks about opportunities in life sciences today.

He shares his take on topics such as how the Baby KJ news is allowing investors and companies to think about scaling bespoke therapies, how AI might start to impact the clinical trial side of our business, and why he sees pharma adoption of AI as being important.

He comments on Abivax, Corvus, Iovance, Legend, Terns, and more. Chapters General sentiment - 0:48 Abivax - 2:14 Corvus - 5:46 Iovance - 7:32 Legend - 9:56 Terns - 11:47

She discusses uniQure, Moderna, BridgeBio, Gossamer Bio and more. Chapters General take on biotech - 0:36 uniQure - 1:43 Moderna - 4:34 BridgeBio - 7:04 Gossamer Bio - 8:07 Other catalysts - 9:36

He believes that the sector's fundamentals are strong and that M&A, which played a central role in boosting biotech last year, can keep up in 2026. Plus, he believes there is a good supply of quality IPOs in the queue that can meet demand that has been there for a while.

He describes his work in these diseases and how Oxford-Harrington has provided funding and advice that has been valuable beyond the feedback he typically receives in an academic setting.

He highlights the centre's Scholars program, which researchers anywhere can apply for and funds ten new drug development programs each year. Plus the centre's accelerator program and plans for a rare disease investment fund. He also discusses how regulatory changes at places like MHRA can help the rare disease community.